Literature DB >> 29978477

MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125.

Chen Liang1,2,3,4, Si Shi1,2,3,4, Qingcai Meng1,2,3,4, Dingkong Liang1,2,3,4, Jie Hua1,2,3,4, Yi Qin1,2,3,4, Bo Zhang1,2,3,4, Jin Xu1,2,3,4, Quanxing Ni1,2,3,4, Xianjun Yu1,2,3,4.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive gastrointestinal tumors, with an overall 5-year survival rate less than 8%. The dismal prognosis is mainly due to aggressive potential for metastasis. Hence, there is an urgent need for a better understanding of the molecular mechanisms underlying pancreatic cancer invasion and metastasis to improve the unfavorable overall survival (OS) of PDAC patients. In this study, we identified microRNA-29a (miR-29a) as an important tumor suppressor, which was downregulated in PDAC tissues. Moreover, miR-29a counteracted MUC16-mediated migration and invasion. In the pancreatic cancer cells, MUC16 upregulated c-Myc expression, which enhanced c-Myc binding to E-box in the miR-29a promoter and inhibited miR-29a transcription. Thus, miR-29a was negatively correlated with both MUC16 expression and serum CA125 levels. Furthermore, caveolin 2 (CAV2) was demonstrated to be the target of miR-29a by bioinformatics and luciferase reporter assays, and high CAV2 expression was responsible for a poor prognosis, especially in the subgroup with normal CA125 levels. Thus, the present study explains why high levels of serum CA125 are correlated with PDAC metastasis, highlighting the predictive value of this marker in PDAC patients.
© 2018 UICC.

Entities:  

Keywords:  MUC16/CA125; caveolin 2; metastasis; miR-29a; pancreatic cancer

Mesh:

Substances:

Year:  2018        PMID: 29978477     DOI: 10.1002/ijc.31654

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.

Authors:  Chen Liang; Jin Xu; Qingcai Meng; Bo Zhang; Jiang Liu; Jie Hua; Yiyin Zhang; Si Shi; Xianjun Yu
Journal:  Autophagy       Date:  2019-06-17       Impact factor: 16.016

2.  Prognostic value of microRNAs in pancreatic cancer: a meta-analysis.

Authors:  Fei Zhao; Chao Wei; Meng-Ying Cui; Qiang-Qiang Xia; Shuai-Bin Wang; Yue Zhang
Journal:  Aging (Albany NY)       Date:  2020-05-18       Impact factor: 5.682

3.  microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF.

Authors:  Qingyuan Shi; Jinhua Dai; Lizhen Huang
Journal:  Iran J Basic Med Sci       Date:  2019-05       Impact factor: 2.699

4.  MiR-29a function as tumor suppressor in cervical cancer by targeting SIRT1 and predict patient prognosis.

Authors:  Ping Nan; Yugui Niu; Xiuhua Wang; Qiang Li
Journal:  Onco Targets Ther       Date:  2019-08-26       Impact factor: 4.147

5.  CAV2 Regulates Mir-4723/Wnt7A Signalling Axis through Endocytosis and Epithelial-Mesenchymal Transition to Promote Proliferation, Invasion, and Metastasis of Pancreatic Cancer Cells.

Authors:  Dan Li; Yuting Guo; She Tian; Changhao Zhu; Chengyi Sun
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

6.  A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.

Authors:  Qingcai Meng; Chen Liang; Jie Hua; Bo Zhang; Jiang Liu; Yiyin Zhang; Miaoyan Wei; Xianjun Yu; Jin Xu; Si Shi
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

7.  Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer.

Authors:  Feng Jiao; Ting Han; Cuncun Yuan; Yiyi Liang; Jiujie Cui; Meng Zhuo; Liwei Wang
Journal:  Cancer Cell Int       Date:  2020-02-18       Impact factor: 5.722

Review 8.  Caveolae as Potential Hijackable Gates in Cell Communication.

Authors:  Maria Dudãu; Elena Codrici; Cristiana Tanase; Mihaela Gherghiceanu; Ana-Maria Enciu; Mihail E Hinescu
Journal:  Front Cell Dev Biol       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.